Zhongsheng Pharma

Guangdong Zhongsheng Pharmaceutical is a comprehensive Chinese pharmaceutical enterprise specializing in the research, development, and manufacturing of chemical drugs and Traditional Chinese Medicines (TCM). The company maintains a dominant market position in ophthalmology, cardiovascular, and respiratory therapeutic areas within China, supported by a robust portfolio of proprietary TCM products. Through its innovative subsidiary, Zhongsheng Ruichuang, the company has aggressively expanded into small molecule drug discovery, focusing on infectious diseases and metabolic disorders. Key milestones include the commercial launch of Raynodovi for COVID-19 and the late-stage development of Onradivir for influenza. Zhongsheng operates multiple GMP-certified manufacturing bases and is recognized for its transition from a traditional manufacturer to an innovation-led biopharmaceutical player.